Article
Hematology
Emmanuel Bachy, Roch Houot, Pierre Feugier, Krimo Bouabdallah, Reda Bouabdallah, Emmanuelle Nicolas Virelizier, Marie Maerevoet, Christophe Fruchart, Sylvia Snauwaert, Steven Le Gouill, Jean-Pierre Marolleau, Lysiane Molina, Cecile Molucon-Chabrot, Catherine Thieblemont, Herve Tilly, Fontanet Bijou, Corinne Haioun, Eric Van den Neste, Bettina Fabiani, Michel Meignan, Guillaume Cartron, Gilles Salles, Olivier Casasnovas, Franck Morschhauser
Summary: The combination of Obinutuzumab and lenalidomide has shown promising clinical efficacy and a manageable safety profile in various types of lymphoma. This study reported the efficacy and safety results for previously untreated patients with advanced follicular lymphoma. The combination treatment resulted in a high complete response rate, overall response rate, and favorable progression-free survival and overall survival. The most common adverse event was neutropenia.
Article
Oncology
Franck Morschhauser, Loretta Nastoupil, Pierre Feugier, Jean-Marc Schiano de Colella, Herve Tilly, Maria Lia Palomba, Emmanuel Bachy, Christophe Fruchart, Edward N. Libby, Rene-Olivier Casasnovas, Ian W. Flinn, Corinne Haioun, Herve Maisonneuve, Loic Ysebaert, Nancy L. Bartlett, Kamal Bouabdallah, Pauline Brice, Vincent Ribrag, Steven Le Gouill, Nicolas Daguindau, Stephanie Guidez, Gian Matteo Pica, Alejandro Martin Garcia-Sancho, Armondo Lopez-Guillermo, Jean-Francois Larouche, Kiyoshi Ando, Maria Gomes da Silva, Marc Andre, Wu Kalung, Laurie H. Sehn, Koji Izutsu, Guillaume Cartron, Argyrios Gkasiamis, Russell Crowe, Luc Xerri, Nathan H. Fowler, Gilles Salles
Summary: The second interim analysis of the RELEVANCE trial after 6 years of follow-up showed that lenalidomide plus rituximab provided similar efficacy to rituximab plus chemotherapy in patients with advanced-stage follicular lymphoma. It demonstrated comparable, durable efficacy and safety, offering a chemo-free alternative for previously untreated patients with FL.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Oncology
Grzegorz S. Nowakowski, Annalisa Chiappella, Randy D. Gascoyne, David W. Scott, Qingyuan Zhang, Wojciech Jurczak, Muhit Ozcan, Xiaonan Hong, Jun Zhu, Jie Jin, David Belada, Juan Miguel Bergua, Francesco Piazza, Heidi Mocikova, Anna Lia Molinari, Dok Hyun Yoon, Federica Cavallo, Monica Tani, Kazuhito Yamamoto, Koji Izutsu, Koji Kato, Myron Czuczman, Sarah Hersey, Adrian Kilcoyne, Jacqueline Russo, Krista Hudak, Jingshan Zhang, Steve Wade, Thomas E. Witzig, Umberto Vitolo
Summary: The ROBUST study aimed to compare the efficacy of lenalidomide plus R-CHOP with placebo/R-CHOP in previously untreated ABC-type DLBCL. While the primary end point of progression-free survival (PFS) was not met in all patients, there were trends favoring R2-CHOP over placebo/R-CHOP in patients with higher-risk disease. The safety profile of R2-CHOP was consistent with individual treatments with no new safety signals.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Review
Oncology
Yurou Chu, Yingyue Liu, Zhuoya Yu, Linquan Zhan, Tiange Lu, Yujie Jiang, Xiaosheng Fang, Xiangxiang Zhou, Xin Wang
Summary: This study conducted a systematic review and meta-analysis to evaluate the maintenance or consolidation strategy for patients with advanced follicular lymphoma. The results showed that obinutuzumab and rituximab maintenance treatment significantly improved progression-free survival (PFS). However, further validation in larger populations is needed to confirm the clinical benefit.
Article
Oncology
Pier Luigi Zinzani, Thomas Rodgers, Dario Marino, Maurizio Frezzato, Anna Maria Barbui, Claudia Castellino, Erika Meli, Nathan H. Fowler, Gilles Salles, Bruce Feinberg, Nuwan C. Kurukulasuriya, Sascha Tillmanns, Stephan Parche, Debarshi Dey, Gunter Fingerle-Rowson, Sumeet Ambarkhane, Mark Winderlich, Grzegorz S. Nowakowski
Summary: The study demonstrated the additional treatment effect achieved by combining tafasitamab with lenalidomide in patients with R/R DLBCL, showing higher overall response rate, complete response rate, and improved survival endpoints compared to lenalidomide monotherapy.
CLINICAL CANCER RESEARCH
(2021)
Article
Oncology
Yong-Pyo Lee, Jung Yong Hong, Sang Eun Yoon, Junhun Cho, Joon-Ho Shim, Yeonghak Bang, Won Seog Kim, Seok Jin Kim
Summary: This study retrospectively analyzed the efficacy of lenalidomide plus rituximab in patients with relapsed or refractory DLBCL. The results showed that this combination therapy may be a salvage option, especially for cases with secondary CNS involvement, but additional agents may be needed to prolong the duration of response.
CANCER MANAGEMENT AND RESEARCH
(2021)
Article
Hematology
Cedric Menard, Delphine Rossille, Joelle Dulong, Tien-Tuan Nguyen, Ilenia Papa, Maelle Latour, Nadege Bescher, Isabelle Bezier, Myriam Chouteau, Thierry Fest, Roch Houot, Franck Morschhauser, Karin Tarte
Summary: The study found that lenalidomide activated T cells in patients with FL, triggering gene changes related to effector memory T cell features, which were validated at the phenotypic and functional levels. Additionally, high effector T cell and regulatory T cell percentages had a negative clinical impact before and during treatment.
Article
Oncology
Sanjal H. Desai, Betsy LaPlant, William R. Macon, Rebecca L. King, Yucai Wang, David J. Inwards, Ivana Micallef, Patrick B. Johnston, Luis F. Porrata, Stephen M. Ansell, Thomas M. Habermann, Thomas E. Witzig, Grzegorz S. Nowakowski
Summary: The study analyzed the effectiveness of lenalidomide plus R-CHOP (R2CHOP) in patients with untreated transformed/concurrent DLBCL, showing promising results in both concurrent and transformed DLBCL. The study supports the inclusion of anthracycline-naive transformed and concurrent DLBCL in future clinical trials of novel immunomodulatory analogues.
BLOOD CANCER JOURNAL
(2021)
Article
Hematology
Anas Younes, John M. Burke, Catherine Diefenbach, Silvia Ferrari, Cyrus Khan, Jeff P. Sharman, Monica Tani, Chaitra Ujjani, Umberto Vitolo, Sam Yuen, Aparna Raval, Mahesh Shivhare, Tina G. Nielsen, Gila Sellam, Michael Gilbertson
Summary: In previously untreated FL patients, the safety and efficacy of atezo-G-bendamustine were evaluated. The complete response rate of this regimen was 75.0%, and the 3-year investigator-assessed PFS and overall survival rates were 80.9% and 89.3%, respectively. However, atezo-G-bendamustine did not appear to show superior efficacy compared to G-bendamustine, and the addition of atezo was associated with an increased risk of adverse events.
Review
Chemistry, Medicinal
Umut Yilmaz, Ayse Salihoglu, Teoman Soysal
Summary: Follicular lymphoma (FL) is a low-grade malignancy of B cells with variable clinical presentations, natural courses, and severity, requiring multiple lines of treatment. Chemoimmunotherapy is the standard care, but alternative treatments are limited for refractory or unfit patients. Lenalidomide combination with rituximab (LR) has shown promising results in clinical trials, offering superior efficacy to monotherapy options.
DRUG DESIGN DEVELOPMENT AND THERAPY
(2021)
Article
Hematology
Jia Ruan, Jasmine Zain, Brett Palmer, Borko Jovanovic, Xinlei Mi, Alok Swaroop, Jane N. Winter, Leo I. Gordon, Reem Karmali, Jonathan Moreira, Adam M. Petrich, Barbara Pro
Summary: This study evaluated the combination of romidepsin and lenalidomide as initial treatment for PTCL and found that it is feasible and effective, showing promising overall response rates and survival outcomes.
Article
Hematology
Tycel J. Phillips, David Bond, Radihka Takiar, Karson Kump, Malalthi Kandarpa, Philip Boonstra, Tera Lynn Mayer, Victoria Nachar, Ryan A. Wilcox, Shannon A. Carty, Yasmin H. Karimi, Zaneta Nikolovska-Coleska, Mark S. Kaminski, Alex F. Herrera, Kami Maddocks, Leslie Popplewell, Alexey V. Danilov
Summary: The combination of lenalidomide, rituximab, and venetoclax is a safe and effective regimen in patients with untreated mantle cell lymphoma (MCL).
Article
Oncology
Stefano Luminari, Martina Manni, Sara Galimberti, Annibale Versari, Alessandra Tucci, Carola Boccomini, Lucia Farina, Jacopo Olivieri, Luigi Marcheselli, Luca Guerra, Simone Ferrero, Luca Arcaini, Federica Cavallo, Sofya Kovalchuk, Tetiana Skrypets, Ilaria del Giudice, Stephane Chauvie, Caterina Patti, Caterina Stelitano, Francesca Ricci, Antonello Pinto, Gloria Margiotta Casaluci, Vittorio R. Zilioli, Anna Merli, Marco Ladetto, Silvia Bolis, Vincenzo Pavone, Annalisa Chiarenza, Annalisa Arcari, Antonella Anastasia, Alessandra Dondi, Donato Mannina, Massimo Federico
Summary: Compared to 2-year rituximab maintenance, metabolic and molecular response-adapted therapy showed inferior progression-free survival in patients with follicular lymphoma. Standard rituximab maintenance demonstrated better efficacy, especially in patients achieving complete metabolic response and MRD-negative.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Medicine, General & Internal
Michael L. Wang, Wojciech Jurczak, Mats Jerkeman, Judith Trotman, Pier L. Zinzani, David Belada, Carola Boccomini, Ian W. Flinn, Pratyush Giri, Andre Goy, Paul A. Hamlin, Olivier Hermine, Jose-Angel Hernandez-Rivas, Xiaonan Hong, Seok Jin Kim, David Lewis, Yuko Mishima, Muhit Ozcan, Guilherme F. Perini, Christopher Pocock, Yuqin Song, Stephen E. Spurgeon, John M. Storring, Jan Walewski, Jun Zhu, Rui Qin, Todd Henninger, Sanjay Deshpande, Angela Howes, Steven Le Gouill, Martin Dreyling
Summary: The combination therapy of Ibrutinib with standard chemoimmunotherapy significantly prolonged progression-free survival in patients with untreated mantle-cell lymphoma, and the safety profile was consistent with the known profiles of the individual drugs.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Hematology
Catherine Diefenbach, Brad S. Kahl, Andrew McMillan, Javier Briones, Lalita Banerjee, Raul Cordoba, Fiona Miall, John M. Burke, Jamie Hirata, Yanwen Jiang, Joseph N. Paulson, Yi Meng Chang, Lisa Musick, Pau Abrisqueta
Summary: Obinutuzumab combined with polatuzumab vedotin or lenalidomide showed promising tolerability and activity in previous trials for relapsed or refractory follicular lymphoma. This study aimed to investigate the efficacy of the novel Pola-G-Len combination in enhancing antitumor response. The results demonstrated high complete response rates and support further investigation of Pola-G-Len in a larger patient population.
LANCET HAEMATOLOGY
(2021)
Letter
Hematology
Caroline Algrin, Louis Perol, Elise Chapiro, Lucile Baseggio, Karim Maloum, Catherine Settegrana, Jean-Francois Lesesve, Justine Siavellis, Alain Delmer, Anne-Sophie Michallet, Emmanuelle Ferrant, Pierre Feugier, Cecile Tomowiak, Annie Brion, David Ghez, Luc-Matthieu Fornecker, Sarah Ivanoff, Stephanie Struski, Laurent Sutton, Isabelle Radford-Weiss, Virginie Eclache, Christine Lefebvre, Veronique Leblond, Florence Nguyen-Khac, Damien Roos-Weil, Innovative Leukemia Org
Article
Oncology
Olivier Hermine, Linmiao Jiang, Jan Walewski, Andre Bosly, Catherine Thieblemont, Michal Szymczyk, Christiane Pott, Gilles Salles, Pierre Feugier, Kai Hubel, Corinne Haioun, Rene Olivier Casasnovas, Christian Schmidt, Kamal Bouabdallah, Vincent Ribrag, Lothar Kanz, Jan Durig, Bernd Metzner, David Sibon, Morgane Cheminant, Barbara Burroni, Wolfram Klapper, Wolfgang Hiddemann, Michael Unterhalt, Eva Hoster, Martin Dreyling
Summary: Clinical Trial Updates provide an opportunity to disseminate additional results from studies for which the primary end point has already been reported. This study confirms the previously observed substantially prolonged time to treatment failure and shows an improvement in overall survival for patients with Mantle Cell Lymphoma. Some patients with MCL may be cured.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Ana Alarcon Tomas, Joshua A. Fein, Shalev Fried, Jessica R. Flynn, Sean M. Devlin, Warren B. Fingrut, Theodora Anagnostou, Anna Alperovich, Nishi Shah, Ellen Fraint, Richard J. Lin, Michael Scordo, Connie Lee Batlevi, Michal J. Besser, Parastoo B. Dahi, Ivetta Danylesko, Sergio Giralt, Brandon S. Imber, Elad Jacoby, Meirav Kedmi, Arnon Nagler, M. Lia Palomba, Mikhail Roshal, Gilles A. Salles, Craig Sauter, Noga Shem-Tov, Avichai Shimoni, Joachim Yahalom, Ronit Yerushalmi, Gunjan L. Shah, Abraham Avigdor, Miguel-Angel Perales, Roni Shouval
Summary: Persistence or recurrence of large B-cell lymphoma after CD19-CAR-T is common and associated with poor prognosis. Novel agents such as polatuzumab and lenalidomide may have potential as treatment options.
Letter
Oncology
David Qualls, Ariela Noy, David Straus, Matthew Matasar, Craig Moskowitz, Venkatraman Seshan, Ahmet Dogan, Gilles Salles, Anas Younes, Andrew D. Zelenetz, Connie Lee Batlevi
LEUKEMIA & LYMPHOMA
(2023)
Article
Multidisciplinary Sciences
Julien Broseus, Sebastien Hergalant, Julia Vogt, Eugen Tausch, Markus Kreuz, Anja Mottok, Christof Schneider, Caroline Dartigeas, Damien Roos-Weil, Anne Quinquenel, Charline Moulin, German Ott, Odile Blanchet, Cecile Tomowiak, Gregory H. Lazarian, Pierre Rouyer, Emil Chteinberg, Stephan Bernhart, Olivier Tournilhac, Guillaume Gauchotte, Sandra Lomazzi, Elise Chapiro, Florence Nguyen-Khac, Celine Chery, Frederic Davi, Mathilde Hunault, Remi Houlgatte, Andreas Rosenwald, Alain Delmer, David Meyre, Marie-Christine Bene, Catherine Thieblemont, Peter Lichter, Ole Ammerpohl, Jean-Louis Gueant, Romain Guieze, Jose Ignacio Martin-Subero, Florence Cymbalista, Pierre Feugier, Reiner Siebert, Stephan Stilgenbauer
Summary: This study characterizes the DNA methylation and transcriptomic profiles of Richter syndrome (RS), and develops classifiers for RS-type de novo diffuse large B-cell lymphomas (DLBCLs).
NATURE COMMUNICATIONS
(2023)
Review
Cell Biology
Mostafa Ejtehadifar, Sara Zahedi, Paula Gameiro, Jose Cabecadas, Maria Gomes da Silva, Hans C. Beck, Ana Sofia Carvalho, Rune Matthiesen
Summary: Mass spectrometry-based proteomics has identified proteins as diagnostic, prognostic, and druggable targets in diffuse large B cell lymphoma. We reviewed these studies and extracted the most consistently significantly regulated proteins, including interferon regulatory factor4, annexinA5, and nucleobindin1.
Article
Hematology
Narendranath Epperla, Jeffrey Switchenko, Veronika Bachanova, James N. Gerson, Stefan K. Barta, Max J. Gordon, Alexey Danilov, Natalie S. Grover, Stephanie Mathews, Madelyn Burkart, Reem Karmali, Yazeed Sawalha, Brian T. Hill, Nilanjan Ghosh, Steven I. Park, David A. Bond, Mehdi Hamadani, Timothy S. Fenske, Peter Martin, Mary-Kate Malecek, Brad S. Kahl, Christopher R. Flowers, Brian K. Link, Lawrence D. Kaplan, David J. Inwards, Andrew L. Feldman, Eric D. Hsi, Kami Maddocks, Kristie A. Blum, Nancy L. Bartlett, James R. Cerhan, John P. Leonard, Thomas M. Habermann, Matthew J. Maurer, Jonathon B. Cohen
Summary: The study aims to evaluate the impact of diagnosis to treatment interval (DTI) on prognosis in newly diagnosed mantle cell lymphoma (MCL) patients. It was found that patients with short DTI had worse prognosis and were associated with adverse clinical factors and poor outcomes. Therefore, DTI should be considered and selection bias should be avoided in the treatment of MCL patients.
Article
Oncology
Serena Zheng, Kanika Gupta, Piyush Goyal, Reiko Nakajima, Laure Michaud, Connie Lee Batlevi, Paul A. Hamlin, Steven Horwitz, Anita Kumar, Matthew J. Matasar, Alison J. Moskowitz, Craig H. Moskowitz, Ariela Noy, M. Lia Palomba, David J. Straus, Gottfried Von Keudell, Lorenzo Falchi, Joachim Yahalom, Andrew D. Zelenetz, Anas Younes, Gilles Salles, Heiko Schoeder, Erel Joffe
Summary: This study discusses the limitations of using interim PET for decision-making and prognosis in the frontline management of Hodgkin's lymphoma. It presents data suggesting that patients who continue treatment with ABVD despite not achieving a complete metabolic response on interim PET may have better outcomes than previously thought. The study also compares the performance of different methods for evaluating PET positivity. Overall, the results indicate that a subset of patients can continue ABVD treatment without a poor outcome, regardless of the criteria for PET2 positivity.
Article
Hematology
Anne-Sophie Michallet, Remi Letestu, Magali Le Garff-Tavernier, Lydia Campos, Michel Ticchioni, Marie-Sarah Dilhuydy, Stephane Morisset, Valerie Rouille, Beatrice Mahe, Kamel Laribi, Bruno Villemagne, Emmanuelle Ferrant, Olivier Tournilhac, Alain Delmer, Lysiane Molina, Veronique Leblond, Cecile Tomowiak, Sophie de Guibert, Frederique Orsini-Piocelle, Anne Banos, Philippe Carassou, Guillaume Cartron, Luc Mathieu Fornecker, Loic Ysebaert, Caroline Dartigeas, Margot Truchan-Graczyk, Jean-Pierre Vilque, Therese Aurran Schleinitz, Florence Cymbalista, Stephane Lepretre, Vincent Levy, Florence Nguyen-Khac
Summary: In previously untreated, medically fit patients with chronic lymphocytic leukemia (CLL), a fixed-duration immunochemotherapy approach yielded deep and sustained peripheral blood measurable residual disease (MRD) responses, high survival rates, and low long-term toxicity. A randomized trial is needed to compare this approach with a chemotherapy-free strategy. The ICLL-07 trial demonstrated promising results with 4-year progression-free and overall survival rates of 95.5% and 96.2%, respectively.
Article
Hematology
Narendranath Epperla, Qiuhong Zhao, Reem Karmali, Pallawi Torka, Lauren Shea, Timothy S. Oh, Andrea Anampa-Guzman, Heather Reves, Montreh Tavakkoli, Irl Brian Greenwell, Emily Hansinger, Elvira Umyarova, Kaitlin Annunzio, Yazeed Sawalha, Beth Christian, Colin Thomas, Stefan K. Barta, Praveen Ramakrishnan Geethakumari, Nancy L. Bartlett, Natalie S. Grover, Adam J. Olszewski
Summary: The presence of M-protein at diagnosis is associated with inferior progression-free survival in patients with marginal zone lymphoma. Immunochemotherapy may be a preferred approach over rituximab monotherapy for patients with M-protein positivity.
Article
Hematology
Nancy L. Bartlett, Sarit Assouline, Pratyush Giri, Stephen J. Schuster, Chan Y. Cheah, Matthew Matasar, Gareth P. Gregory, Dok Hyun Yoon, Mazyar Shadman, Keith Fay, Sung-Soo Yoon, Carlos Panizo, Ian Flinn, Anna Johnston, Francesc Bosch, Laurie H. Sehn, Michael C. Wei, Shen Yin, Iris To, Chi-Chung Li, Huang Huang, Antonia Kwan, Elicia Penuel, Lihua E. Budde
Summary: This study confirmed the efficacy and safety of mosunetuzumab monotherapy in patients with relapsed/refractory diffuse large B-cell lymphoma. Some patients had previously received chimeric antigen receptor T-cell therapy. Cytokine release syndrome was the most common adverse event.
Article
Hematology
A. Martin Garcia-Sancho, M. Baile, G. Rodriguez, I. Dlouhy, J. M. Sancho, I. Jarque, E. Gonzalez-Barca, A. Salar, M. Espeso, C. Grande, J. Bergua, S. Montes-Moreno, A. Redondo, A. Enjuanes, E. Campo, A. Lopez-Guillermo, D. Caballero
Summary: The study evaluated the addition of lenalidomide to R-ESHAP regimen (LR-ESHAP) for the treatment of relapsed or refractory DLBCL patients. The overall response rate after 3 cycles was 67%, with a lower response rate observed in patients with primary refractory disease (54%). LR-ESHAP shows promising efficacy in patients with RR DLBCL.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Medicine, General & Internal
Carole Durot, Eric Durot, Sebastien Mule, David Morland, Francois Godard, Anne Quinquenel, Alain Delmer, Philippe Soyer, Christine Hoeffel
Summary: The purpose of this study was to determine whether texture features on pretreatment unenhanced CT images derived from 18F-FDG PET/CT can predict survival outcomes in patients with high-tumor-burden follicular lymphoma treated with immunochemotherapy and rituximab maintenance. The study found that skewness at a fine texture scale and kurtosis without filtration were independent predictors of progression-free survival and time to next treatment. The results suggest that pretreatment unenhanced CT texture analysis-derived skewness and kurtosis can be used as predictive biomarkers for survival outcomes in patients with high-tumor-burden follicular lymphoma.
Article
Hematology
Claire Roddie, Lazaros J. Lekakis, Maria A. V. Marzolini, Aravind Ramakrishnan, Yiyun Zhang, Yanqing Hu, Vijay G. R. Peddareddigari, Nushmia Khokhar, Robert Chen, Silvia Basilico, Meera Raymond, Frederick Arce Vargas, Kevin Duffy, Wolfram Brugger, Maeve A. O'Reilly, Leigh Wood, David C. Linch, Karl S. Peggs, Carlos Bachier, Elizabeth Lihua Budde, Connie Lee Batlevi, Nancy Bartlett, David Irvine, Eleni Tholouli, Wendy Osborne, Kirit M. Ardeshna, Martin A. Pule
Summary: This study evaluated the efficacy of CD19/22 dual-targeting CAR-T (AUTO3) plus pembrolizumab in relapsed/refractory large B-cell lymphoma. The results showed that the AUTO3 plus pembrolizumab treatment regimen was safe for patients and provided durable remissions in complete responders.
Article
Hematology
Ana Carolina Freitas, Tiago Maia, Joana Desterro, Francesca Pierdomenico, Albertina Nunes, Isabelina Ferreira, Jose Cabecadas, Maria Gomes da Silva
Summary: Myelodysplastic/myeloproliferative neoplasms (MDS/MPN) are a diverse group of diseases that are increasingly classified based on recurrent genetic abnormalities. Chromosomal translocations involving meningioma 1 (MN1) and ETS variant 6 (ETV6) genes are rare but common in myeloid neoplasms. We present a case of MDS/MPN with neutrophilia that developed an extramedullary T-lymphoblastic crisis with the t(12;22)(p13;q12) translocation as the only cytogenetic abnormality. This case shares characteristics with myeloid/lymphoid neoplasms with eosinophilia and highlights the importance of molecular characterization in classification and prognostic stratification.
HEMATOLOGY REPORTS
(2023)